Department of Radiology, School of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, USA.
Department of Radiology, School of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, USA.
Nucl Med Biol. 2022 Nov-Dec;114-115:65-70. doi: 10.1016/j.nucmedbio.2022.09.002. Epub 2022 Sep 26.
Solid-phase synthesis and conjugation reactions of acids and amines using coupling reagents are common in organic synthesis, but rare in F radiochemistry. 4-[F]Fluorobenzoic acid (FBA) is a useful building block, but is seldom used directly with coupling reagents for the preparation of F radiopharmaceuticals. To overcome the inconveniences associated with using [F]FBA in conjugation reactions, we have developed a non-covalent solid-phase synthesis (SPS) strategy for the radiosynthesis of [F]PARPi, a derivative of olaparib as a Poly (ADP-ribose) polymerase-1 (PARP-1) radioligand.
Fluoro-, bromo- and iodo-benzoic derivatives of olaparib were synthesized, and their PARP-1 affinities were measured using a recently developed cell culture-based competitive assay. To produce [F]PARPi, [F]FBA was radiosynthesized and purified using a cation-exchange cartridge, and then trapped by an anion-exchange resin cartridge, on which the solid-phase radiosynthesis was carried out to produce the desired product. [F]PARPi was evaluated in vivo in breast and prostate xenograft tumor models by microPET imaging, biodistribution and autoradiography.
The best derivatives of olaparib were identified as compound 4, 7 and 8. [F]4 ([F]PARPi) was radiosynthesized in high radiochemical yield, high molar activity and high radiochemical purity using this SPS strategy. The in vivo evaluation of [F]PARPi demonstrates the PARP-1 specific uptake of [F]PARPi in the animal models.
This method is simple and efficient, having great potential for the synthesis of radiopharmaceuticals starting from [F]FBA or other radiolabeled aromatic acids. Using [F]PARPi prepared by this method, we demonstrated the promise of [F]PARPi in the nuclear imaging of PARP-1 expression.
在有机合成中,使用偶联试剂进行固相合成和酸与胺的偶联反应是很常见的,但在 F 放射性化学中却很少见。4-[F]氟苯甲酸(FBA)是一种有用的构建块,但很少直接与偶联试剂一起用于制备 F 放射性药物。为了克服在偶联反应中使用 [F]FBA 带来的不便,我们开发了一种非共价固相合成(SPS)策略,用于合成 [F]PARPi,一种奥拉帕利的衍生物,作为聚(ADP-核糖)聚合酶-1(PARP-1)放射性配体。
合成了氟代、溴代和碘代奥拉帕利的苯甲酸衍生物,并使用最近开发的基于细胞培养的竞争测定法测量了它们对 PARP-1 的亲和力。为了制备 [F]PARPi,使用阳离子交换柱对 [F]FBA 进行放射性合成和纯化,然后用阴离子交换树脂柱捕获,在其上进行固相放射性合成以产生所需产物。通过 microPET 成像、生物分布和放射自显影在乳腺癌和前列腺异种移植肿瘤模型中评估了 [F]PARPi 的体内活性。
鉴定出奥拉帕利的最佳衍生物为化合物 4、7 和 8。使用这种 SPS 策略,以高放射化学产率、高摩尔活性和高放射化学纯度成功地放射性合成了 [F]4([F]PARPi)。[F]PARPi 的体内评估表明,[F]PARPi 在动物模型中具有 PARP-1 特异性摄取。
该方法简单高效,具有从 [F]FBA 或其他放射性标记的芳香酸合成放射性药物的巨大潜力。使用这种方法制备的 [F]PARPi,我们证明了 [F]PARPi 在 PARP-1 表达的核成像中的应用前景。